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Catastrophic costs incurred by tuberculosis (TB) patients have received considerable atten-
tion, however little is known about costs and pathways to care after a negative TB
evaluation.
Materials and methods
We conducted a cross-sectional study of 70 patients with a negative TB evaluation at four
community health centres in rural and peri-urban Uganda. Patients were traced 9 months
post-evaluation using contact information from TB registers. We collected information on
healthcare visits and implemented locally-validated costing questionnaires to assess the
financial impact of their symptoms post-evaluation.
Results
Of 70 participants, 57 (81%) were traced and 53 completed the survey. 31/53 (58%) sur-
veyed participants returned to healthcare facilities post-evaluation, making a median of 2
visits each (interquartile range [IQR] 1–3). 11.3% (95%CI 4.3–23.0%) of surveyed patients
and 16.1% (95%CI 5.5–33.7%) of those returning to healthcare facilities incurred cata-
strophic costs (i.e., spent >20% annual household income). Indirect costs related to lost
work represented 80% (IQR 32–100%) of total participant costs.
Conclusions
Patients with TB symptoms who experience financial catastrophe after negative TB evalua-
tion may represent a larger absolute number of patients than those suffering from costs due
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to TB. They may not be captured by existing definitions of non-TB catastrophic health
expenditure.
Introduction
Whilst the incidence and mortality of tuberculosis (TB) are declining globally, they are not
declining fast enough to meet the ambitious targets set out in the World Health Organization’s
(WHO) END TB strategy [1]. This strategy highlights the need for bold social policies and
research in addition to patient-centred care in order to eliminate TB. To this end, there has
been increased interest in the diagnostic journey of TB patients and their financial costs as
they represent potential opportunities for novel interventions and programmatic development
(1,2).
The severe economic implications of a TB diagnosis in lower and middle income countries
have been well described [2, 3]. The proportion of patients incurring catastrophic costs
(defined as>20% annual household income (AHI)) whilst obtaining a TB diagnosis and treat-
ment serves as a measure of the financial burden of TB. Eliminating catastrophic costs for TB
affected households is one of the three key targets in the END TB strategy [1, 4, 5]. However,
much less attention has been paid to those who test negative during TB evaluation. These
patients represent the vast majority of those embarking upon the TB diagnostic journey. Even
in high TB-burden settings such as Uganda, 80–90% of patients with chronic cough will have a
negative evaluation for TB [6–8]. Though they likely do not have the disease, persistent symp-
toms may lead patients to seek alternative diagnoses and therapies even after their negative TB
evaluation. It is currently unclear to what extent these patients are at risk of incurring punitive
costs in the pursuit of such a solution.
Studies of TB patients suggest that costs due to lost work represent a considerable propor-
tion of their total financial burden [4] leading the END TB strategy to include lost income and
non-medical cost in the calculation of ‘catastrophic costs’ in TB patients [9]. By contrast, finan-
cial risk in non-TB patients with similar respiratory symptomatology only considers out-of-
pocket medical costs, termed by WHO as ‘catastrophic health expenditure’ [10]. It is not
known to what extent non-TB patients suffer from non-medical and indirect costs that may
not be captured under this current definition.
Previous studies have shown TB-negative individuals are likely to incur catastrophic costs
prior to testing when their TB status is unknown [11]. However, to our knowledge, the finan-
cial burden accumulated after a negative TB evaluation has not been evaluated. We sought to
characterise the number and type of healthcare providers visited by patients after a negative
TB evaluation in Uganda and to estimate both the direct and indirect costs they incurred in
following these pathways of care.
Materials and methods
Ethics statement
Ethical approval was granted by institutional review boards at the London School of Hygiene
and Tropical Medicine (London, UK; MSc Ethics Ref: 15360), Makerere College of Health Sci-
ences (Kampala, Uganda; REC Ref 2016–037) and University of California San Francisco (San
Francisco, California, USA; ref:221338 IRB# 15–17296). Written consent was obtained for all
in person interviews. Oral consent was taken and recorded for all telephone interviews.
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Study setting
This exploratory cross-sectional study was carried out in four geographically-distinct areas of
Uganda, two peri-urban and two rural, all within 150km of Kampala. Study sites were selected
from those participating in XPEL TB trial, a cluster randomized trial to evaluate the effective-
ness and implementation of onsite GeneXpert testing at community health centres [12]. One
community-level TB microscopy centre was selected at random per a priori-defined area from
those participating in the trial. Each of these centres uses sputum smear microscopy as the pri-
mary method of diagnosis for TB, tests more than 150 patients a year and refers sputum sam-
ples to a district or regional facility for Xpert MTB/Rif testing as part of the Uganda national
TB program Xpert referral network.
Participants
Potential participants were identified from TB laboratory registers routinely kept at the four
centres. Adult patients (�18 years) who could consent and had a negative TB test result at
these centres in quarter three and four of 2017 were eligible for inclusion. Individuals with a
positive TB test result or who started treatment for TB within 2 weeks of their original evalua-
tion were excluded. A convenience sample of 70 eligible individuals was taken. Preference was
shown for individuals with recorded mobile telephone information, but in all other respects
sampling was random. Participants were traced approximately 9 months after their negative
test (Fig 1). Once traced, participants were given information about the study purpose and
procedures and then asked to provide informed consent. If contacted by telephone, partici-
pants were read a standardised information and consent script and asked to consent over the
phone–this was recorded as an audio data file.
Surveys
All traced participants found to be alive were surveyed in participants’ local languages. Partici-
pants found to have died had the approximate date and reported cause of death recorded.
Information was collected for up to ten healthcare facility visits made after a participant’s nega-
tive TB evaluation. This included the number and type of facility and time taken to visit. Cost
data was collected for the post-evaluation period using locally-validated questionnaires
adapted from the WHO patient costs survey for TB [9]. The adapted tool is presented in the
Supplementary information. Costs incurred prior to and during TB evaluation were not evalu-
ated. Participants were asked to estimate the cost of each component part of their visit (e.g.,
travel expenses, medication) including the value of any lost income. Total direct (out-of-
pocket costs, split into medical e.g., medication, and non-medical e.g., transport) and indirect
(lost income) costs were calculated. Total indirect costs per participant were calculated by tak-
ing a fraction of reported annual personal income based on the reported number of days of
work lost due to symptoms post-TB evaluation. Dissavings were defined as the sum of reported
borrowing, selling of assets and taking-out of loans. Cost data were collected in Ugandan Shil-
lings (USh) and reported in both United States Dollars ($) and as a proportion of pre-morbid
annual household income. During the data collection period the median nominal exchange
rate was 3,680USh to $1USD; this was used calculate and report results in USD.
Data analysis
Patient characteristics, costs and healthcare-seeking behaviours were described using propor-
tions with 95% confidence intervals for dichotomous outcomes and medians with inter-quar-
tile ranges for non-parametric continuous outcomes. Wilcoxon Rank Sum tests were used to
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assess statistical differences in time and cost data between dichotomous variables. Univariate
and multivariable sub-analyses were conducted using logistic and linear regression for binary
and continuous dependent variables respectively. All data were analysed in STATA (version
15, StataCorp USA).
Ethical approval was granted by institutional review boards at the London School of
Hygiene and Tropical Medicine (London, UK), Makerere College of Health Sciences (Kam-
pala, Uganda) and University of California San Francisco (San Francisco, California, USA).
Results
Participants
Tracing was successful in 57/70 individuals (81%). Four traced individuals had died. Of the
remaining 53, all consented to being surveyed. Surveys were administered a median of 10
months following negative TB evaluation (range 8–14 months). The 13 untraced individuals
were younger than the 57 traced participants (mean difference -14.5 years 95%CI -23.3 - -5.7).
No other statistically significant difference was found between these groups.
The 53 surveyed participants had a median age of 40 (IQR 32–51), 28 (53%) were female
(Table 1). Thirty-three were traced by phone (62%). Median AHI (mAHI) was $1,174 (IQR
$489–$3,261). Eighty-seven percent (n = 46) visited another healthcare facility before present-
ing for TB evaluation, making a median of 3 visits (IQR 2–5) pre-evaluation.
Fig 1. Participant tracing procedure. NOK = next of kin; VHT = village health team.
https://doi.org/10.1371/journal.pone.0253927.g001
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Most participants were evaluated for TB with smear microscopy (n = 47, 89%); the remain-
der were evaluated with Xpert MTB/Rif. Twenty-eight percent were not aware of the result of
their evaluation. Six participants (11.3%; 95%CI 4–23%) reported being diagnosed with TB
more than 2 weeks after their negative index evaluation and had subsequently been started on
anti-tuberculous therapy.
Pathways to care
Symptoms persisted for a median of 4 weeks post-evaluation (IQR 3–13) in surveyed individu-
als (n = 53), causing a median loss of 7 days of work (IQR 1–30). Twenty-two participants
made no further visit to any health facility post-evaluation. The remaining 31 participants
(58%) made a total of 83 visits to healthcare post-evaluation, a median of 2 visits each (IQR
1–3) (Fig 2). Fig 3 shows a flowchart detailing pathways to care.
Participants spent a median of 20 minutes travelling (IQR 10–60) and 2 hours visiting (IQR
1.25–5) per facility visit. The most commonly visited facilities were private clinics or hospitals,
constituting 36% of all visits made. Local pharmacies (22%) and level III or IV government
health centres (23%) were also commonly visited.
Costs of healthcare seeking behaviour post-evaluation
Participants (n = 53) incurred a median of $16.46 total costs post-TB evaluation (IQR $7.07-
$93.33). Direct and indirect costs represented 20% (IQR 0–68%) and 80% (IQR 32–100%) of
total costs respectively. Participants lost a median of $13.17 in indirect costs (IQR $1.05-
$65.84). For those who accessed healthcare post-evaluation (n = 31), direct costs were a
median of $8.97 (IQR $3.40-$30.57). Out-of-pocket medical costs represented 68% (IQR 59–
86%) of total direct costs.
The median cost of a facility visit was $10.19 (IQR $4.35-$28.53) (Table 2). Of the 83 visits
made, medical costs occurred in 62 visits and non-medical costs in 72 visits. Purchase of
Table 1. Characteristics of surveyed participants.
Patient characteristics Number/median
(percentage/IQR)
Age (years) 40 (32–51)
Sex Male 25 (47)
Female 28 (53)
HIV status Positive 27 (51)
Negative 24 (45)
Unknown 2 (4)
Living Environment Rural 29 (55)
Urban-/Peri-urban 24 (45)
Mobile phone ownership Yes 35 (66)
No 18 (34)
Tracing method Mobile phone 33 (62)
Address 20 (38)
Test type used in the initial negative TB evaluation Smear Microscopy 47 (89)
Xpert MTB/Rif 6 (11)
Awareness of negative TB test result Aware 38 (72)
Not aware 15 (28)
Total number of surveyed participants = 53
https://doi.org/10.1371/journal.pone.0253927.t001
PLOS ONE Pathways to care and catastrophic costs following negative TB evaluation in Uganda
PLOS ONE | https://doi.org/10.1371/journal.pone.0253927 July 16, 2021 5 / 12
medicines was the most frequent medical cost, occurring in 56 (67%) visits. In 38 visits these
costs represented the only medical cost. Radiology was the most expensive type of medical cost
with a median cost of $6.79. However, it was only accessed in 6 of 83 (7%) visits. Travel costs
were the most common type of non-medical direct cost, incurred in 64 of 83 (77%) visits.
Food costs were incurred in 32/83 visits and represented a median of 33% (IQR 24–68%) of
non-medical costs when they occurred. The fraction of total direct participant expenditure
represented by different cost categories is presented in Fig 4.
In total, 11% (95%CI 4.3–23.0%) of study participants spent >20% of AHI post-TB evalua-
tion, incurring catastrophic costs. This amounted to 16.1% (95%CI 5.5–33.7%) of the 31
patients who accessed healthcare post-evaluation. Total financial losses were not significantly
greater in those who attended healthcare post-evaluation, although they trended towards
being so (median $40.61 [attended] vs $13.64 [did not attend]; p = 0.09). All participants suf-
fering catastrophic costs experienced symptoms for more than 6 weeks post-evaluation.
Of surveyed individuals (n = 53), 66% (95%CI 51.7–78.5%) suffered dissavings post-evalua-
tion. They incurred a median loss of $32.61 (IQR $10.87-$206.52), equivalent to 1.8% of AHI.
Borrowing money was the most common form of dissaving (21/53) whilst selling assets
incurred the largest median loss ($70.65, IQR $21.74-$353.26). Dissavings were significantly
more common amongst participants who attended care post-evaluation (p = 0.04). However,
the magnitude of dissaving did not vary between those who attended care post-evaluation and
those who did not (p = 0.6). Catastrophic costs trended towards being more common in those
that incurred dissavings (p = 0.07).
Discussion
Patients with chronic cough whose evaluation for TB is negative, although considered to be
‘completed’ from the perspective of National TB Programmes, remain patients with ongoing
symptoms sufficiently troubling as to prompt further healthcare-seeking. More than 10% of
individuals experienced financial catastrophe after negative TB evaluation without even con-
sidering costs incurred prior to or during TB evaluation. In TB patients these pre-diagnostic
costs represent 48–53% of total expenditure [4]. Spending of this magnitude is sufficiently
prevalent to warrant the attention of primary healthcare programs.
Fig 2. The distribution of healthcare facility visits made by study participants after TB evaluation.
https://doi.org/10.1371/journal.pone.0253927.g002
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Despite a negative evaluation for TB, many individuals continue to search for diagnostic
and therapeutic solutions. Although a significant minority did not visit any further facility,
more than half did so, some many times over. These results are consistent with the likely range
of aetiologies of chronic cough in this setting [13]. The sickest and hardest to diagnose patients
may repeatedly access care without resolution, whilst those with self-limiting infectious ill-
nesses require little, if any, further medical attention. However, a lack of accurate diagnostic
data means this interpretation warrants further study. Visits to the private sector predomi-
nated, contributing 61% of all post-evaluation healthcare episodes. This is consistent with
other studies of pathways to care in high-TB burden settings [14, 15].
Many participants experienced significant financial burden from their symptoms post-evalu-
ation, and 11% financial catastrophe. Although this study did not include pre-evaluation costs,
the authors and others have previously documented the potential for these costs to be financially
catastrophic [4, 11]. Our study shows that for some, these costs do not stop after a negative test
for TB. Taken together, the proportion of individuals with non-tuberculous chronic cough
experiencing financial catastrophe during their diagnostic journey is likely higher than reported
here. TB-negative individuals represent the majority of patients undergoing evaluation for TB.
At a community level they could constitute as large a total financial burden as those with the
disease. This cost burden likely reflects not only unwell and difficult-to-diagnose individuals
who repeatedly access care but also the high indirect cost of seeking healthcare in this environ-
ment relative to income. The high burden of indirect costs in this study mirrors those found to
occur in TB-affected households, which are characterised by lost income, inability to work and
job loss [4, 16–19]. The fact that 28% of participants did not return to receive the results of their
TB test is further suggestion that accessing healthcare in this environment is prohibitively
expensive for some. The cost of accessing healthcare in lower- and middle-income countries is
known to be financially challenging for many and often leads to dissaving and other coping
strategies not traditionally assessed in financial risk protection research [20].
There were several limitations to this study. Firstly, the methodology predisposes costing
information to recall bias. Steps were taken to mitigate this by making survey questions as
unambiguous as possible. Nevertheless, cost findings need to be interpreted with a degree of
caution. Second, the study’s cross-sectional design does not allow for definitive conclusions to
be drawn on causality between observed associations. Last, this study did not include costs
incurred prior to evaluation, which limits the extent to which firm conclusions can be drawn
Fig 3. Patient pathways to care after TB evaluation. Flowchart showing patient pathways to care after TB evaluation. To the right of each facility
visit, coloured boxes represent the types of facilities participants visited (see Key). Numbers within the boxes represent the number of participants
visiting that type of facility. Blank boxes indicate that facility type was not visited. If a participant visited a further facility, their next visit is
recorded at the next step of the flow chart. If a participant did not visit a further facility, they exit the flow chart to the left of their current facility
visit. CHW = Community Health Worker.
https://doi.org/10.1371/journal.pone.0253927.g003
Table 2. Participant costs per facility visit.
Total cost per facility
visit (IQR)
Direct cost per facility
visit (IQR)
Direct medical costs per
facility visit (IQR)




Median cost 10.19 6.79 4.35 1.36 2.72
($ USD) (4.35–28.53) (2.58–16.30) (0–11.41) (0.54–4.07) (0–13.59)
Median cost as a percentage
of mAHI (%)
0.9% 0.6% 0.4% 0.1% 0.2%
(0.4–2.4) (0.2–1.4) (0–1.0) (0.04–0.3) (0–1.2)
Costs per facility visit in absolute terms and as a percentage of median annual household income; n = 83. USD = United States Dollar, mAHI = median annual
household income, IQR = interquartile range.
https://doi.org/10.1371/journal.pone.0253927.t002
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regarding the total cost incurred by participants during their illness. Despite these limitations,
this study focuses on a patient group that has been comparatively neglected by international
health research and presents important insights into the financial implications of their health
issues. The generalisability of our findings could be seen as a limitation as we purposefully did
not institute complex sampling procedures to make our subjects completely representative of
the population they are derived from. However, the aim of the study was to describe the situa-
tion in these areas of Uganda in order to illustrate issues that could be widespread, rather than
to derive specific generalisable conclusions. Of note, rates of phone ownership in study partici-
pants are consistent with those of the general population in Uganda [21, 22].
The move towards universal health coverage (UHC), advocated by the WHO as a possible
solution to catastrophic health expenditure, may help patients surmount the financial barriers
to medical costs for non-TB illnesses. However, UHC-related interventions by themselves will
likely not be sufficient to mitigate financial catastrophe for patients as medical costs are only
one driver of total patient cost [4, 18, 23]. Parallel social protection initiatives to prevent or
reduce non-medical and indirect costs are likely to be essential as these costs make up a signifi-
cant proportion of patient expenditure. These initiatives have been proven to mitigate such
costs in TB patients [24]. Furthermore, under the current definition of catastrophic health
expenditure advocated by the WHO, these non-medical and indirect costs are excluded when
assessing the financial stress on non-TB patients [10]. A definition of financial catastrophe that
accounts for the important financial burdens that non-direct medical costs and indirect costs
create would support identification of affected patients and allow health programs to better
select and target interventions.
Conclusions
Far from avoiding the catastrophic costs incurred by many of their TB-positive counterparts,
some individuals continue to experience financial catastrophe after negative TB evaluation.
Fig 4. Distribution of direct costs during facility visits by study participants. Direct costs incurred in 83 facility
visits by the 31 study participants who returned to healthcare after TB evaluation. Slices represent the percentage of
overall direct costs incurred by study participants by cost category (percentages labelled). The number of visits in
which the specified cost category was accessed is also shown on the slices in brackets. The inner legend shows the
median and inter-quartile range (in brackets) spent in that cost category, when accessed.
https://doi.org/10.1371/journal.pone.0253927.g004
PLOS ONE Pathways to care and catastrophic costs following negative TB evaluation in Uganda
PLOS ONE | https://doi.org/10.1371/journal.pone.0253927 July 16, 2021 9 / 12
They may represent a larger economic burden at a community level than those suffering from
similar costs due to TB and may not be captured by existing definitions of non-TB catastrophic
health expenditure. A prospective longitudinal study with recruitment at the point of TB eval-
uation would allow more accurate cost estimation, capture of final diagnoses and allow explo-
ration of alternative definitions of financial catastrophe and their relationship to outcomes.
Furthermore, such a study could be designed to prospectively compare the costs after both a
positive and negative TB evaluation from the same population. Meanwhile, more attention
needs to be paid to encouraging TB-negative patients to return to the clinic that tested them to
coordinate further investigative efforts.
Supporting information
S1 Table. Multivariable logistic regression of factors associated with increased odds of
attending healthcare facilities after negative TB evaluation. n = 51 for analysis (due to
n = 51 known HIV status). OR = odds ratio; TB = tuberculosis. All variables found to be associ-
ated with accessing healthcare post-evaluation with a significance level of p�0.1 in the univari-
ate analysis were included in the multivariable analysis along with age and sex. A longer
duration of symptoms after TB evaluation was associated with increased odds of attending
healthcare facilities post-evaluation. Subjects living in rural settings and those with HIV infec-
tion had lower odds. Four or more healthcare attendances prior to TB evaluation trended
towards association with increased odds of attendance post-evaluation but was non-signifi-
cant.
(PDF)
S2 Table. Univariate logistic regression analysis comparing the unadjusted odds of attend-
ing healthcare facilities by study participants after negative TB evaluation. n = 51 for analy-
sis (due to n = 51 known HIV status). OR = odds ratio; TB = tuberculosis; NTLP = National
Tuberculosis and Leprosy Program. Variables that demonstrated an association with a signifi-
cance level of p�0.1 were taken through to multivariable analysis along with age and sex.
(PDF)
S3 Table. Univariate linear regression analysis comparing the unadjusted total cost
incurred by participants after negative TB evaluation. n = 51 for analysis (due to n = 51
known HIV status). TB = tuberculosis; USh = Ugandan Shillings; NTLP = National Tubercu-
losis and Leprosy Program.
(PDF)
S1 File. Modified costing tool. This tool was adapted from a validated costing tool used in
previous work by our group [11]. No questions related to financial expenditure were added or
subtracted from the original costing tool. Additional questions were added to aid in discrimi-
nating different pathways to care used by study participants.
(PDF)
S2 File. Raw data for analysis.
(XLSX)
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